Media
Press releases and topics in the spotlight
Welcome to our media section. Check out the latest interviews, news, and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information.
Latest pressreleases
In the spotlight
A new paradigm shift driven by acid control
Highlights from the 2024 Annual Report: Market overview. 24-hour acid control is the most important characteristic to differentiate an acid-suppressive drug and to create optimal healing conditions.
Addressing an unmet medical need in GERD
Highlights from the 2024 Annual Report: Market overview. Significant proportion of severe eGERD patients treated by Gastroenterologists remain unhealed with PPI treatment.
We develop the future GERD treatment which has roots in AstraZeneca
Highlights from the 2024 Annual Report: Interview with the founders. Cinclus Pharma, founded by a team of experts with deep roots in the pharmaceutical industry, is on a mission to bring an effective GERD treatment, linaprazan glurate, to the market…
A Doctor’s perspective on linaprazan glurate’s unique potential
Highlights from the 2024 Annual Report: Interview with Dr. Prateek Sharma. Dr. Prateek Sharma, Medical Advisor and expert in gastrointestinal diseases and cancer, shares his insights on its safety and potential usage areas.
Cinclus Pharma in media
Kjell Andersson in the Lonza Podcast: A View On: Developing Acid Reflux Therapy
2025-03-06Kjell Anderson, Chief Scientific Officer and Founder of Cinclus Pharma, discusses a novel treatment for acid reflux in this episode ‘A View On: Developing Acid Reflux Therapy’ of the Lonza podcast.
Placera.se lists Swedish stocks offering the biggest upside
2025-01-02Cinclus Pharma is on the list of analysts' favorite stocks when Placera.se lists Swedish stocks offering the biggest upside.
Bengt Julander on Cinclus Pharma in DITV
2024-12-11Bengt Julander, Chairman of one of Cinclus Pharma's largest shareholders, Linc, participated in DITV, saying Cinclus Pharma has the world's best stomach ulcer treatment.
Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
2024-11-28Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
Cinclus Pharma's CEO Christer Ahlberg interviewed by Redeye
2024-09-23Cinclus Pharma's CEO Christer Ahlberg was interviewed by Okee Williams at Redeye AB on September 23, about the company and the development of the drug candidate linaprazan glurate.
